Business
ENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019
‒ Three Month Biomarker Data from Phase 2 Clinical Trial of EB613 Expected in the Second Quarter of 2020 with Additional Data Readouts Expected in 2020 and
About this update from Entera Bio Ltd.
[{"type":"text","content":"‒ Three Month Biomarker Data from Phase 2 Clinical Trial of EB613 Expected in the Second Quarter of 2020 with Additional Data Readouts Expected in 2020 and Early 2021 ‒‒ Financing Completed in December 2019 Funds Company into the Second Quarter of 2021 ‒‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒\n BOSTON and JERUSALEM, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced its financial and operational results for the quarter and year ended December 31, 2019. “Over the last several weeks we have seen significant changes across the world due to the spread of COVID-19 and the resulting impact on our employees, clinical trials, and the financial markets. We have developed risk mitigation and contingency plans that prioritize the safety of our patients and employees, balanced carefully with a goal of maintaining our operations and clinical trials according to the changing government and hospital regulations. Despite the uncertainty and impact from COVID-19, we have a balance sheet, that with our recently completed $14.3 million financing, provides us with funding into the second quarter of 2021, which we believe positions us well to achieve a number of important milestones in 2020,” stated Adam Gridley, CEO of Entera. “With multiple potential data readouts from our Phase 2 dose-ranging study of EB613 in osteoporosis patients and the potential for additional business development collaborations, we are rapidly responding to the emerging COVID-19 challenges to reorient our internal operations and business strategy to ensure Entera can achieve its goal to become a leader in the oral delivery of large molecule therapeutics.” 2019 and Recent Milestones Initiated dose-ranging, placebo-controlled, Phase 2 clinical trial of EB613 and have enrolled 98 patients, or more than 60% of the total: In July 2019, Entera initiated a dose-ranging, placebo-controlled, Phase 2 clinical trial in female patients with osteoporosis, or low bone mineral density (BMD). Based on feedback from the United States Food and Drug Administration (the FDA) in late 2018, Entera expects this trial, if successful, to position the Company for the initiation of a single, global Phase 3 non-inferiority registration trial with a BMD endpoint c...